168 related articles for article (PubMed ID: 29627620)
1. Efficacy, safety, and tolerability of lubiprostone for the treatment of non-alcoholic fatty liver disease in adult patients with constipation: The LUBIPRONE, double-blind, randomised, placebo-controlled study design.
Kessoku T; Imajo K; Kobayashi T; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Saito S; Nakajima A
Contemp Clin Trials; 2018 Jun; 69():40-47. PubMed ID: 29627620
[TBL] [Abstract][Full Text] [Related]
2. Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial.
Kessoku T; Imajo K; Kobayashi T; Ozaki A; Iwaki M; Honda Y; Kato T; Ogawa Y; Tomeno W; Kato S; Higurashi T; Yoneda M; Kirikoshi H; Kubota K; Taguri M; Yamanaka T; Usuda H; Wada K; Kobayashi N; Saito S; Nakajima A
Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):996-1007. PubMed ID: 32805205
[TBL] [Abstract][Full Text] [Related]
3. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
[TBL] [Abstract][Full Text] [Related]
4. Response to lubiprostone in chronic constipation is associated with increased mucus and mucin output: a randomized clinical trial.
Tarasiuk A; Milad M; Ahmed ST; Majewski M; Wallner G; Fichna J; Bashashati M; Sarosiek J
J Gastrointestin Liver Dis; 2019 Sep; 28(3):263-264. PubMed ID: 31517334
[No Abstract] [Full Text] [Related]
5. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
[TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
7. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial.
Cui J; Philo L; Nguyen P; Hofflich H; Hernandez C; Bettencourt R; Richards L; Salotti J; Bhatt A; Hooker J; Haufe W; Hooker C; Brenner DA; Sirlin CB; Loomba R
J Hepatol; 2016 Aug; 65(2):369-76. PubMed ID: 27151177
[TBL] [Abstract][Full Text] [Related]
8. The Effect of Probiotics (MCP
Mohamad Nor MH; Ayob N; Mokhtar NM; Raja Ali RA; Tan GC; Wong Z; Shafiee NH; Wong YP; Mustangin M; Nawawi KNM
Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579068
[TBL] [Abstract][Full Text] [Related]
9. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.
Newsome PN; Palmer M; Freilich B; Sheikh MY; Sheikh A; Sarles H; Herring R; Mantry P; Kayali Z; Hassanein T; Lee HM; Aithal GP;
J Hepatol; 2020 Aug; 73(2):231-240. PubMed ID: 32234329
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of PERIOdontal treatment versus usual care for Nonalcoholic liver disease: protocol of the PERION multicenter, two-arm, open-label, randomized trial.
Kamata Y; Kessoku T; Shimizu T; Kobayashi T; Kurihashi T; Sato S; Kuraji S; Aoyama N; Iwasaki T; Takashiba S; Hamada N; Kodama T; Tamura T; Ino S; Higurashi T; Taguri M; Yamanaka T; Yoneda M; Usuda H; Wada K; Nakajima A; Minabe M
Trials; 2020 Mar; 21(1):291. PubMed ID: 32293522
[TBL] [Abstract][Full Text] [Related]
11. Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease.
Scorletti E; Afolabi PR; Miles EA; Smith DE; Almehmadi A; Alshathry A; Moyses HE; Clough GF; Wright M; Patel J; Bindels L; Delzenne NM; Calder PC; Byrne CD
Contemp Clin Trials; 2018 Aug; 71():113-123. PubMed ID: 29787859
[TBL] [Abstract][Full Text] [Related]
12. Lubiprostone improves intestinal permeability in humans, a novel therapy for the leaky gut: A prospective randomized pilot study in healthy volunteers.
Kato T; Honda Y; Kurita Y; Iwasaki A; Sato T; Kessoku T; Uchiyama S; Ogawa Y; Ohkubo H; Higurashi T; Yamanaka T; Usuda H; Wada K; Nakajima A
PLoS One; 2017; 12(4):e0175626. PubMed ID: 28410406
[TBL] [Abstract][Full Text] [Related]
13. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
[TBL] [Abstract][Full Text] [Related]
14. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lubiprostone for the treatment of functional constipation in Chinese adult patients: A multicenter, randomized, double-blind, placebo-controlled trial.
Xiao YL; Dai N; He SX; Tian A; Liu S; Tian ZB; Wang XY; Li YQ; Hou XH; Fang XC; Wen ZL; Zeng WZ; Xu H; Sun MJ; Liu YL; Wu YD; Shen XZ; Liu XW; Liu L; Chen MH
J Dig Dis; 2021 Nov; 22(11):622-629. PubMed ID: 34633753
[TBL] [Abstract][Full Text] [Related]
16. The Role of Leaky Gut in Nonalcoholic Fatty Liver Disease: A Novel Therapeutic Target.
Kessoku T; Kobayashi T; Tanaka K; Yamamoto A; Takahashi K; Iwaki M; Ozaki A; Kasai Y; Nogami A; Honda Y; Ogawa Y; Kato S; Imajo K; Higurashi T; Hosono K; Yoneda M; Usuda H; Wada K; Saito S; Nakajima A
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360923
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
Sun Y; Chen G; Chen S; Wang Y; Hu Y; Zhao Y
Trials; 2022 Jun; 23(1):455. PubMed ID: 35655225
[TBL] [Abstract][Full Text] [Related]
18. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.
Newsome PN; Sasso M; Deeks JJ; Paredes A; Boursier J; Chan WK; Yilmaz Y; Czernichow S; Zheng MH; Wong VW; Allison M; Tsochatzis E; Anstee QM; Sheridan DA; Eddowes PJ; Guha IN; Cobbold JF; Paradis V; Bedossa P; Miette V; Fournier-Poizat C; Sandrin L; Harrison SA
Lancet Gastroenterol Hepatol; 2020 Apr; 5(4):362-373. PubMed ID: 32027858
[TBL] [Abstract][Full Text] [Related]
19. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
Armstrong MJ; Gaunt P; Aithal GP; Barton D; Hull D; Parker R; Hazlehurst JM; Guo K; ; Abouda G; Aldersley MA; Stocken D; Gough SC; Tomlinson JW; Brown RM; Hübscher SG; Newsome PN
Lancet; 2016 Feb; 387(10019):679-690. PubMed ID: 26608256
[TBL] [Abstract][Full Text] [Related]
20. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
Faghihzadeh F; Adibi P; Hekmatdoost A
Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
